FDA cleared a Besremi prefilled pen as a second delivery option to the prefilled syringe, with no changes to indication, dose schedule, or established safety profile. Ropeginterferon alfa-2b is ...

AbbVie’s largest deal in more than half a decade adds a group of immune disease medications — among them a Dupixent ...

AbbVie agreed to acquire Apogee Therapeutics for $135.11 per share in cash, valuing the clinical-stage biotechnology company at approximately $10.9 billion, the companies said Monday. Both boards have ...

Sponsored by Regeneron and Sanofi. It was a perfect day for a shark dive. The skies were blue and the water off Guadalupe Island was crystal clear. Shane, a software engineer by trade and adventurer ...

The U.S. Food and Drug Administration has approved Sanofi and Regeneron's Dupixent (dupilumab) for the treatment of children (aged 2 to 11 years) with chronic spontaneous urticaria (CSU). This ...

Dupixent is the first biologic approved for chronic spontaneous urticaria in patients as young as 2 years of age. The Food and Drug Administration (FDA) has expanded the approval of Dupixent ® ...

During its first-quarter conference call, Sanofi highlighted its effort to extend its patent protection for Regeneron-partnered Dupixent. The immunology blockbuster accounted for 40% of the company's ...

At six feet tall, it’s no surprise that Diana Taurasi was drawn to basketball. “It's my passion, it's my love,” she says of the sport. Taurasi, who retired in February 2025 after 20 seasons playing ...

Connect Biopharma has reported 52-week improvements across multiple endpoints in a phase 3 trial of its eczema drug candidate, fueling the biotech’s belief that its molecule is better than Dupixent.

Dupixent is a prescription medication that can help manage chronic inflammatory conditions in children, such as eczema, asthma, and eosinophilic esophagitis. It can be exhausting for a child to ...

What Is Dupixent, and Why Does It Matter? Dupixent (dupilumab) is a prescription medicine for treating various allergic conditions and is given as a shot under the skin. The FDA has now approved ...

Many people living with rheumatoid arthritis (RA) rely on long-term medications to manage joint pain, stiffness, and inflammation. A number of these treatments are given as subcutaneous injections, ...